Hypertonic saline in the treatment of patients with cystic fibrosis in Russian Federation

Introduction. Mucolytic therapy is basic in the treatment of patients with cystic fibrosis (CF). Currently, inhalation of hypertonic saline (HS) of NaCl is recommended for the treatment of CF patients. The aim of the study was to investigate the experience of the use of HS NaCl for inhalations CF patients in the Russian Federation. Material and methods. To estimate the use of HS NaCl, data of national registers for 2011–2019 were used. Pharmacoeconomic analysis of “HS 7% NaCl + 0.1% sodium hyaluronate”, presented in the Russian market, carried out according to the cost estimate for the course of therapy based on the cost from the site of the unified information system in the sphere of procurement. Results. From 2011 to 2019, an increase in the number of patients receiving the inhalation of a HS is observed. 2011 –8.7% of patients with CF, by 2019 – in 71.5% of CF patients. In 25 regions of the Russian Federation more than 80% of CF patients used HS NaCl. The cost analysis of Russian-made medicinal products for human use containing 7% HS and 0.1% sodium hyaluronate solution, and foreign-made products of similar composition showed that the annual cost of therapy with Russian-made products was 2.15 times lower than that with the foreign-made products. As for the medicinal product mannitol, the annual cost of therapy with a foreign-made product is 8.1 times higher than the cost of a Russian-made product. Conclusions. The clinical practice of treating patients with CF has accumulated positive use of HS in inhalations, the use of which has increased significantly since 2011. Medical products 3 and 7% HS with a 0.1% solution of sodium hyaluronate are prescribed from the moment of diagnosis and have advantages over the HS pharmacy production over portability and ease of use. The use of the “7% HS with a 0.1% solution of sodium hyaluronate” is mainly determined by the financial accessibility.